NEW YORK, NY — (Marketwire) — 03/18/13 — TriMarkPublications.com cites in its newly published “” report that (TDM) will spike to $2.69 billion by 2019. For more information, visit: .
can be categorized into seven main modalities: antiepileptics, antiarrhythmics, antibiotics, antineoplastics, bronchodilators, immunosuppressives and HIV/AIDS drugs. The global market is dominated by eight major suppliers that account for a combined 88.3% of the global market. The U.S. market is expected to grow to $1.84 billion by 2019 at a CAGR of 12.6%.
The “” report covers:
Chemiluminescence
High Pressure Liquid Chromatography (HPLC)
Gas Chromatography/Mass Spectrometry
Liquid Chromatography/Mass Spectrometry
Flucytosine
Triazoles
Itraconazole
Voriconazole
Posaconazole
Enzyme Immunoassays
Enzyme Multiplied Immunoassay Technique
Cloned Enzyme Donor Immunoassays
Radio Immunoassays
Fluorescence Polarization Immunoassays
Lateral Flow Immunoassays
Particle Enhanced Turbidimetric Inhibition Immunoassays
Affinity Chrome Mediated Immunoassays
The “” report examines companies manufacturing equipment and supplies in the world. Companies covered include: Abaxis, Abbott, Alere, Alfa Wassermann, AMS, Beckman Coulter, BioMerieux, Carolina Chemistries, DiaSorin, Grifols, Horiba, Medica, Nova Biomedical, Ortho Clinical Diagnostics, Polymedico, Randox, Roche and Siemens.
Detailed charts with sales forecasts and marketshare data are included. For more information, visit: .
TriMarkPublications.com is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit .
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.
TriMarkPublications.com
Media Relations
1-888-OK-TRIMARK